MASH affects >115m people worldwide, but had no approved treatment until a few weeks ago. After >100 clinical trial failures in the field, Rezdiffra (resmetirom) developed by Madrigal Pharmaceuticals received it's FDA approval this month. GLP1s which treat obesity have also shown significant promise in early trials, so it has never been more exciting for the MASLD/MASH and liver disease community.
But, perhaps the biggest challenge is on the horizon: MASH and MASLD are often asymptomatic until they become very serious, so how do we non-invasively screen for people at-risk, so they can get treated before they discover they are cirrhotic and in need of a liver transplant?
Mazen Noureddin, MD, MHSc is a world leader in non-invasive diagnostic tools for MASLD/MASH, through both his academic work at Houston Methodist and as CSO of Summit Clinical Research.
In the episode we cover genetics, proteomics, imaging, resmetirom, GLP1s, precision therapies on the horizon, and much more in this episode! I also had the great opportunity to spend some time with Mazen in person, and you will hopefully get a glimpse of not only his knowledge, but also great sense of humor through the podcast.
Hope you enjoy!!
🎥 A sneak peek from Episode 127 of The Genetics Podcast with Mazen Noureddin, MD, MHSc!
Ever wondered about the next big thing in non-invasive diagnostic tools for fatty liver disease, or upcoming developments in precision medicine research for NASH/MASH? This is a must-listen! 🧬
Want to dive deeper? Watch/listen to the full conversation by clicking the link below 👇 or searching ‘The Genetics Podcast’ on your preferred platform.
https://pod.fo/e/22959e
https://lnkd.in/dHdbxD2X
#genetics #thegeneticspodcast #sanogenetics #precisionmedicine #MASH #MASLD #NASH #NAFLD #liverdisease
